Partners

In addition to advancing our own pipeline, Mersana is accelerating the development of novel ADC therapies for patients in dire need of better treatments through strategic collaborations with leading pharmaceutical and biotech companies.

Mersana entered into a collaboration with Takeda Pharmaceutical Co. in April 2014 to develop antibody drug conjugates using our Fleximer platform and antibodies provided by Takeda. In January 2015, the companies expanded their collaboration to include additional oncology-related targets.

View Press Release

Mersana entered into a collaboration with Merck Serono in June 2014 to develop novel antibody drug conjugates against multiple undisclosed targets using our Fleximer platform and monoclonal antibodies provided by Merck Serono.

View Press Release

Mersana entered into an oncology-focused collaboration with Asana BioSciences, formerly part of Endo Pharmaceuticals, in March 2012 to develop novel antibody drug conjugates using our Fleximer platform and antibodies provided by Asana.

View Press Release